Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies

Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies

On September 21st, Zai Lab, the Chinese biopharma start-up, has officially listed in the United States Nasdaq global market, bagged a total of $150 million. On the same day, its stock rose 55.17%, amount to $27.93 per share.

Zai Lab is not the first Chinese biopharmaceutical company which has completed an IPO in the United States. In the past years, a number of Chinese start-ups in the life science sector has chosen Nasdaq over the Shanghai Stock Exchange for various reasons, largely due to the differences between the Chinese and the US trading systems. Using this opportunity as Zai Lab is entering the US, I would like to introduce a list of Chinese biopharmaceutical companies listed there.

BeiGene
BeiGene was listed on Nasdaq on February 4th, 2016. As of September 21st, 2017, its stock price is closed at $86.25 per share.

BeiGene is a global biopharmaceutical company, dedicated to establishing itself as the leader in innovative molecular targeting medications and anti-tumor immunological drugs. In the past few years, it has been stepping up its effort to expand the territory and actively pushing out a slew of cancer therapies through its pipeline, including BGB-311, BGB-A317, BGB-290, and BGB-283.

Among them, BGB-311, a powerful and highly selective small molecule BTK inhibitor, is currently under evaluation as a monotherapy and also as a combo therapy to treat various lymphomas; BGB-317 is a humanized monoclonal antibody against immunological checkpoint PD-1; BGB-290 is an oral, potent, and highly selective inhibitor against molecular targets PARP1 and PARP2; BGB-283 is a small molecule RAF kinase inhibitor.

BeyondSpring

BeyondSpring has completed its IPO on Nasdaq on March 9th, 2017. As of September 21st, 2017, its stock price is at $39 per share.

BeyondSpring, founded by Dr. Lan Huang the receiver of the “Thousand Talents Program”, is a clinical phase focused biopharma start-up. It specializes in the discovery and development of novel cancer treatments, including immunological drugs against late-stage tumors.

Worth noting is that BeyondSpring currently holds the Chinese and the global patents of innovative anti-cancer drug Plinabulin, along with several other highly efficient small molecule medications.

According to its official website, Plinabulin, a synthetic analog of marine microbial products, can target and change the tumor microenvironment, improving the condition of patients with non-small cell carcinoma and at the same time preventing docetaxel-induced neutropenia.

During its preclinical studies, Plinabulin has shown good safety profiles and antitumor activities in a variety of cancer models, including brain cancer, KRAS mutant tumors, etc., indicating its potential benefits in treating gastrointestinal cancer, breast cancer, prostate cancer, and blood cancers.

Bontac

Shandong Bontac, listed in Nasdaq in 2009, is the only Chinese blood product biopharma which has completed an IPO in the US. As of September 21st, 2017, its stock price is at $92.80 per share.

Bontac, aimed to create an integrated platform for scientific research, production, and commercialization, currently has more than 10 plasma collection stations located in Shandong, Guangxi, and Heibei provinces in China.

Its existing product lines range in 9 categories — human serum albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, tetanus human immunoglobulin, hepatitis B human immunoglobulin, human coagulation factor VIII, human thrombin complex, and Human fibrin — a total of 24 different products.

Chi-Med
Chi-Med was listed on Nasdaq on March 18th, 2016. As of September 21st, 2017, its stock price is at $25.55 per share.

As a subsidiary company under the Chinese billionaire Ka-Shing Li’s CK Hutchison Holdings Limited, Chi-Med is dedicated to discovering, developing, producing and selling medications and supplements to both the Chinese and the global markets.

Its most important innovation platform is Hutchison MediPharma. Currently equipped with more than 300 talents, it has established a comprehensive and complete internal platform, actively pushing forward the discovery and development of novel anti-tumor and anti-autoimmune treatments.

Beijing Sinovac Biotech
Beijing Sinovac Biotech, co-founded by Hongkong Sinovac Biotech and Sinobioway Medicines, is the only Chinese vaccine pharma company listed on Nasdaq.

Its main businesses range from the discovery to the development to the production and sales of human used vaccines, including several marketed products against Enterovirus 71, hepatitis A, influenza, H5N1, H1N1, and mumps.

China Cordblood Corporation
China Cordblood Corporation, the largest professional umbilical cord blood storage organization in China, was listed in Nasdaq on November 19th, 2009. As of September 21st, 2017, its stock price is closed at $11.69 per share.

Currently supporting Beijing, Shandong, and Zhejiang, its main business is to provide a one-stop shop to store and preserve umbilical cord blood stem cells, which includes four different steps — blood collection, blood preparation, laboratory testing, and stem cell storage.

2 Replies to “Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies”

Leave a Reply

Your email address will not be published. Required fields are marked *